- Home
- BRT vs SGMT Comparison
BRT vs SGMT Comparison
Compare BRT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- SGMT
- Stock Information
- Founded
- BRT 1972
- SGMT 2006
- Country
- BRT United States
- SGMT United States
- Employees
- BRT N/A
- SGMT N/A
- Industry
- BRT Real Estate Investment Trusts
- SGMT
- Sector
- BRT Real Estate
- SGMT
- Exchange
- BRT Nasdaq
- SGMT Nasdaq
- Market Cap
- BRT 281.9M
- SGMT 238.7M
- IPO Year
- BRT N/A
- SGMT 2023
- Fundamental
- Price
- BRT $14.44
- SGMT $8.33
- Analyst Decision
- BRT Strong Buy
- SGMT Strong Buy
- Analyst Count
- BRT 1
- SGMT 8
- Target Price
- BRT $19.50
- SGMT $26.88
- AVG Volume (30 Days)
- BRT 46.9K
- SGMT 651.1K
- Earning Date
- BRT 11-06-2025
- SGMT 11-13-2025
- Dividend Yield
- BRT 6.92%
- SGMT N/A
- EPS Growth
- BRT N/A
- SGMT N/A
- EPS
- BRT N/A
- SGMT N/A
- Revenue
- BRT $98,407,000.00
- SGMT N/A
- Revenue This Year
- BRT N/A
- SGMT N/A
- Revenue Next Year
- BRT $4.12
- SGMT N/A
- P/E Ratio
- BRT N/A
- SGMT N/A
- Revenue Growth
- BRT 2.46
- SGMT N/A
- 52 Week Low
- BRT $14.17
- SGMT $1.73
- 52 Week High
- BRT $20.22
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- BRT 31.57
- SGMT 56.14
- Support Level
- BRT $14.63
- SGMT $8.02
- Resistance Level
- BRT $15.21
- SGMT $9.46
- Average True Range (ATR)
- BRT 0.35
- SGMT 0.68
- MACD
- BRT -0.01
- SGMT 0.09
- Stochastic Oscillator
- BRT 7.69
- SGMT 51.08
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.